Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte C Widemann

Showing results (21-30 of 203) with videos related to

Pageof 21
Sort By:
Expert Opinion on Orphan Drugs|August 9, 2020
Developing therapies for rare tumors: opportunities, challenges and progressDiana Bradford, Karlyne M Reilly, Brigitte C Widemann, et al.
Clinical Trials (London, England)|September 30, 2023
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International CollaborationVanessa L Merker, Andrea M Gross, Brigitte C Widemann, et al.
Pediatric Blood & Cancer|August 8, 2013
PET-guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type 1Yilun Koethe, Brigitte C Widemann, Fouad Hajjar, et al.
Cancer Chemotherapy and Pharmacology|March 6, 2015
Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate modelDiane E Cole, Cynthia M Lester-McCully, Brigitte C Widemann, et al.
Journal of Genetic Counseling|July 24, 2017
Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1)Lori Wiener, Haven Battles, Sima Zadeh Bedoya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsBrigitte C Widemann, Wendy Goodspeed, Anne Goodwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trialsAeRang Kim, Eva Dombi, Jeffrey Solomon, et al.
Neuro-Oncology Advances|July 25, 2025
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control armAyo Adeyemi, Andrea M Gross, Andrea Baldwin, et al.
Frontiers in Psychology|January 23, 2024
Development and psychometric testing of a pediatric chronic graft-versus-host disease symptom scale: protocol for a two-phase, mixed methods studySandra A Mitchell, Rachael Hunter, Abigail Fry, et al.
Children (Basel, Switzerland)|June 24, 2022
Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC)Robin Lockridge, Sima Bedoya, Taryn Allen, et al.
Pageof 21

Showing results (21-30 of 203) with videos related to

Sort By:
Pageof 21
Expert Opinion on Orphan Drugs|August 9, 2020
Developing therapies for rare tumors: opportunities, challenges and progressDiana Bradford, Karlyne M Reilly, Brigitte C Widemann, et al.
Clinical Trials (London, England)|September 30, 2023
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International CollaborationVanessa L Merker, Andrea M Gross, Brigitte C Widemann, et al.
Pediatric Blood & Cancer|August 8, 2013
PET-guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type 1Yilun Koethe, Brigitte C Widemann, Fouad Hajjar, et al.
Cancer Chemotherapy and Pharmacology|March 6, 2015
Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate modelDiane E Cole, Cynthia M Lester-McCully, Brigitte C Widemann, et al.
Journal of Genetic Counseling|July 24, 2017
Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1)Lori Wiener, Haven Battles, Sima Zadeh Bedoya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsBrigitte C Widemann, Wendy Goodspeed, Anne Goodwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trialsAeRang Kim, Eva Dombi, Jeffrey Solomon, et al.
Neuro-Oncology Advances|July 25, 2025
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control armAyo Adeyemi, Andrea M Gross, Andrea Baldwin, et al.
Frontiers in Psychology|January 23, 2024
Development and psychometric testing of a pediatric chronic graft-versus-host disease symptom scale: protocol for a two-phase, mixed methods studySandra A Mitchell, Rachael Hunter, Abigail Fry, et al.
Children (Basel, Switzerland)|June 24, 2022
Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC)Robin Lockridge, Sima Bedoya, Taryn Allen, et al.
Pageof 21